Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed renal cell carcinoma~  * Locally advanced unresectable or metastatic disease~* Unidimensionally measurable disease by physical exam or imaging study~  * The following are not considered measurable disease:~    * Bone only disease~   * Pleural or peritoneal effusions~   * CNS lesions~   * Irradiated lesions unless disease progression was documented after radiotherapy~PATIENT CHARACTERISTICS:~Age~* Over 18~Performance status~* ECOG 0-2~Life expectancy~* Not specified~Hematopoietic~* Granulocyte count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic~* ALT and AST \< 3 times upper limit of normal~* Bilirubin ≤ 2.0 mg/dL~Renal~* Creatinine ≤ 2.0 mg/dL~Gastrointestinal~* No active inflammatory bowel disease~* No significant bowel obstruction~* No chronic diarrhea~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 6 months after study participation~* No mental incapacitation or psychiatric illness that would preclude giving informed consent~* No other active malignancy except nonmelanoma skin cancer~* No other severe disease that would preclude study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* At least 4 weeks since prior immunotherapy~* No concurrent prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF)~Chemotherapy~* No prior chemotherapy~* No other concurrent chemotherapy~Endocrine therapy~* No concurrent hormones except steroids for adrenal failure, hormones for non-disease-related conditions (e.g., insulin for diabetes), or intermittent dexamethasone as an antiemetic~Radiotherapy~* See Disease Characteristics~* At least 4 weeks since prior radiotherapy~* No concurrent palliative radiotherapy~Surgery~* Not specified~Other~* No concurrent participation in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Gemcitabine + Irinotecan (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).